Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $46.00 at Wells Fargo & Company

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target hoisted by investment analysts at Wells Fargo & Company from $45.00 to $46.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 76.04% from the stock’s previous close.

A number of other brokerages have also recently issued reports on RARE. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Ultragenyx Pharmaceutical in a report on Monday, August 10th. Barclays decreased their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. Weiss Ratings upgraded Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada lifted their price objective on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $58.29.

Ultragenyx Pharmaceutical Trading Down 0.4%

Shares of NASDAQ:RARE traded down $0.11 on Thursday, reaching $26.13. 1,585,355 shares of the company were exchanged, compared to its average volume of 2,211,932. Ultragenyx Pharmaceutical has a 1-year low of $18.29 and a 1-year high of $39.89. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -4.47 and a beta of 0.35. The company has a 50-day moving average of $28.52 and a 200-day moving average of $24.96.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.32. The firm had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business’s revenue for the quarter was up 28.5% compared to the same quarter last year. During the same quarter last year, the business earned ($1.17) earnings per share. As a group, analysts forecast that Ultragenyx Pharmaceutical will post -4.12 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 1,899 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares in the company, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Howard Horn sold 4,653 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the sale, the chief financial officer directly owned 105,689 shares in the company, valued at $2,512,227.53. This represents a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 8,552 shares of company stock valued at $207,455. 5.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RARE. Palo Alto Investors LP purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $19,916,968,000. Jefferies Financial Group Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $31,040,000. Capstone Investment Advisors LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $549,000. Corient Private Wealth LP acquired a new position in Ultragenyx Pharmaceutical in the second quarter valued at $4,644,000. Finally, Bank of America Corp DE acquired a new position in Ultragenyx Pharmaceutical in the second quarter valued at $38,347,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: GENGLYCOS is the first FDA-approved treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa), a rare metabolic disorder. The therapy could reduce the daily care burden for patients and give Ultragenyx a new commercial growth driver. Reuters article
• Positive Sentiment: The approval is Ultragenyx’s first gene-therapy approval and its fifth FDA approval overall, expanding the company’s marketed product portfolio. Ultragenyx also received a Priority Review Voucher, which could potentially be used or sold for additional value. Ultragenyx announcement
• Positive Sentiment: Wells Fargo described the gene-therapy launch as capable of creating a “long revenue tailwind,” while Cantor Fitzgerald raised its price target to $103 from $96 and maintained an Overweight rating. These targets imply substantial upside, although they are analyst estimates rather than guarantees. Yahoo Finance analyst coverage
• Neutral Sentiment: The accelerated approval supports earlier commercialization, but continued approval generally depends on confirmatory evidence. Investors will focus on launch timing, treatment uptake, pricing, reimbursement and the company’s ability to generate durable revenue.
• Negative Sentiment: RARE had recently weakened ahead of the FDA decision, underscoring that expectations and execution risk remain high. Ultragenyx is still loss-making, so the near-term stock reaction may depend on whether GENGLYCOS sales can materially improve the company’s financial outlook.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.